ArQule, Inc. (NASDAQ: ARQL)

ArQule, Inc. (NASDAQ: ARQL), a biotechnology company, is committed to researching and developing next-generation, small-molecule cancer therapeutics. The company’s lead product, ARQ 197, is currently in clinical-stage development. ArQule’s discovery efforts are focused on identifying novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate), an energy source for cells. For further information, visit the Company’s web site at www.arqule.com.